Stockreport

HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-med [Read more]